Alzheimer's Disease Patents (Class 514/17.8)
  • Patent number: 10882890
    Abstract: Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: January 5, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Benjamin Pang-Hsien Tu, Rita Py Chen, Joseph Jen-Tse Huang, Yijuang Chern, Yu-Song Jang, Xiang-Me Lai, Tai-Yan Liao, Te-Hsien Kung
  • Patent number: 10662226
    Abstract: Synthetic A? peptides, oligomers, their methods of synthesis, and their applications are provided. The A? peptides can form stable, soluble oligomers important for the advancement of knowledge, detection, and treatment of Alzheimer's disease. Antibodies specific to oligomeric A? and their methods of synthesis are also described.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 26, 2020
    Assignee: The Regents of the University of Caiifomia
    Inventors: James S. Nowick, Adam G. Kreutzer, Ryan K. Spencer, Patrick J. Salveson
  • Patent number: 10654894
    Abstract: Novel cell penetrating agents for intracellular delivery of desired cargo, including proteins. Use of cell penetrating agents to deliver cargos to the interior of cells and cellular compartments and organelles is transformative for diagnostic, therapeutic, and research processes.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 19, 2020
    Assignee: KEENESAW STATE UNIVERSITY RESEARCH AND SERVICE FOUNDATION, INC.
    Inventors: Jonathan L. McMurry, John C. Salerno, Scott J. Nowak, Marcus C. Davis, Kathleen Bartlow
  • Patent number: 10548942
    Abstract: The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 4, 2020
    Assignee: STC.UNM
    Inventor: Jeff Wade Hill
  • Patent number: 10308681
    Abstract: The present invention relates to a peptide separated from the fraction of oyster enzyme hydrolysate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrolysate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrolysate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 4, 2019
    Assignees: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Se-Young Choung, Yeung Joon Choi
  • Patent number: 10239923
    Abstract: Peptides specifically binding amyloid beta and to methods of treating and diagnosing Alzheimer's dementia using such peptides are provided.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: March 26, 2019
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Dieter Willbold, Stephan Rudolph, Janine Kutzsche, Susanne Aileen Funke
  • Patent number: 10233222
    Abstract: The invention provides compounds for the treatment of Alzheimer's disease, methods for the use of such compounds, assays for the identification of such compounds, and methods for diagnosis of Alzheimer's disease and diagnostic kits. Methods of marketing compounds are also disclosed. In one aspect, the disclosure provides a compound for the diagnosis or treatment of Alzheimer's disease wherein the compound is a modulator that inhibits the disruption by amyloid ? of a complex comprising synaptophysin and/or synaptobrevin. In another aspect, the disclosure provides a pharmaceutical composition comprising the compounds disclosed herein in an amount sufficient to treat Alzheimer's disease in a subject. In another aspect, the disclosure provides a diagnostic composition comprising the compound disclosed herein.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: March 19, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, AMIDEBIO, LLC
    Inventors: Michael H. B. Stowell, Mikhail Plam
  • Patent number: 10202418
    Abstract: The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: February 12, 2019
    Assignee: MERCK PATENT GMBH
    Inventor: Markus Klein
  • Patent number: 9835633
    Abstract: The present disclosure provides methods of identifying a candidate agent for treating an apoE-associated neurodegenerative disorder. The methods involve contacting a PCSK1 or a PCSK2 polypeptide with an apolipoprotein E polypeptide in the presence of a test agent.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 5, 2017
    Assignee: The J. David Gladstone Institutes
    Inventors: Yadong Huang, Qin Xu
  • Patent number: 9670490
    Abstract: Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase neuronal differentiation, oligodendrocyte differentiation, or neurological outcome or function in a patient in need thereof. Some embodiments also comprise the administration a composition comprising a pharmaceutically effective amount of one or more of a group comprising microRNA-146a, a promoter of microRNA-146a expression, a microRNA-146a mimic, thymosin beta 4, and a phosphodiesterase 5 inhibitor to treat neurological conditions, disease, or injury in mammals, including in human beings.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: June 6, 2017
    Assignee: Henry Ford Health System
    Inventors: Xianshuang Liu, Zhenggang Zhang, Michael Chopp, Lei Wang
  • Patent number: 9540434
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 10, 2017
    Assignees: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • Patent number: 9402883
    Abstract: An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: August 2, 2016
    Assignee: ALPHARETA AB
    Inventor: Jan Johansson
  • Patent number: 9403876
    Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: August 2, 2016
    Assignee: Brown University
    Inventors: Mark Spaller, John Marshall, Dennis J. Goebel
  • Patent number: 9376465
    Abstract: Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: June 28, 2016
    Assignee: UNIVERSITY OF SOUTH CAROLINA
    Inventors: Campbell McInnes, Shu Liu
  • Patent number: 9040078
    Abstract: The invention provides a method for treating a subject suffering from a disease of the central nervous system which is associated with an inflammatory response, including, inter alia, multiple sclerosis, Amyotrophic Lateral Sclerosis (ALS), meningitis, Alzheimer's disease, pain, HIV-associated dementia, stroke, traumatic brain injury, encephalomyelitis, chronic inflammatory demyelinating polyneuropathy, cerebral ischemia-induced injury or any combination thereof. This invention further provides for the use of a conjugate, or composition comprising the same, for treating the subject, wherein the conjugate comprises a lipid or phospholipid moiety bonded to a physiologically acceptable monomer, dimer, oligomer, or polymer.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: May 26, 2015
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventor: Saul Yedgar
  • Publication number: 20150140046
    Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150133388
    Abstract: A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation. The therapeutic polypeptide including at least one of acetylated ?A-crystallin, acetylated ?B-crystallin, acetylated fragments thereof having molecular chaperone activity, and/or polypeptide mimetics thereof that can inhibit pathological protein aggregation and/or pathological apoptosis.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Inventors: Ram Nagaraj, Rooban B. Nahomi
  • Patent number: 9023800
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • Publication number: 20150119336
    Abstract: The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Inventors: Dieter Willbold, Susanne Aileen Funke, Oleksander Brener, Luitgard Nagel-Steger, Dirk Bartnik
  • Patent number: 9018169
    Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: April 28, 2015
    Assignee: Duke University
    Inventors: Daniel T. Laskowitz, Hana Dawson, Brad Kolls
  • Publication number: 20150111828
    Abstract: The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10?9 to 10?5 M.
    Type: Application
    Filed: August 15, 2014
    Publication date: April 23, 2015
    Applicant: UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII
    Inventors: Sergey Borisovich SEREDENIN, Alexandrovna Tatyana GUDASHEVA
  • Patent number: 9011862
    Abstract: The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-? peptide (A?), comprising the steps of a) contacting at least one A? -peptide and/or the nitrated forms thereof with at least one candidate inhibitor that potentially specifically binds to a region in said A? -peptide capable of being nitrated, and b) detecting said inhibitor specifically binding to said region in said A? -peptide through detecting a lack of or a reduced aggregation of said at least one A? -peptide. The present invention is further directed at improved methods for treating neuronal degradation and particularly Alzheimer's disease, based on said inhibitor. The present invention is further directed at methods for diagnosing the aggregation of A? -peptide in the context of neuronal degradation and particularly Alzheimer's disease.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: April 21, 2015
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Michael Thomas Heneka, Markus Peter Kummer
  • Patent number: 9006205
    Abstract: Alzheimer's disease (AD) is the most common human neurodegenerative disease of the CNS resulting in progressive neuronal death and memory loss. Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. It was discovered that antisense oligonucleotide against neutral sphingomyelinase and GW4869, a chemical inhibitor of neutral sphingomyelinase, inhibit activation of glial cells and protect neurons in AD cell culture and animal models. These results suggest the following new treatment options for AD patients: Antisense oligonucleotide against neutral sphingomyelinase and GW4869.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: April 14, 2015
    Assignee: Rush University Medical Center
    Inventor: Kalipada Pahan
  • Publication number: 20150099692
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMBAX CO., LTD., GEMVAX AS
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20150099693
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMVAX CO., LTD., GEMVAX-AS
    Inventors: Sang Jae Kim, Kyun Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20150098989
    Abstract: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 9, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Patent number: 8999927
    Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 7, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Qing-Rong Liu
  • Patent number: 8999936
    Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: April 7, 2015
    Assignee: BioArctic Neuroscience AB
    Inventors: Pär Gellerfors, Lars Lannfelt
  • Patent number: 8986690
    Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: March 24, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Anders Nykjaer, Claus Munck Petersen
  • Patent number: 8987199
    Abstract: In one embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In yet another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions of the invention may be used to treat or prevent a neurodegenerative disorder such as Alzheimer's disease, stroke, Parkinson's disease, multiple sclerosis, spinal cord injuries, and/or traumatic brain injuries and the like, in addition to other systemic and local diseases.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: March 24, 2015
    Assignee: Nerve Access, Inc.
    Inventors: Yaser A. Abdel Maksoud, Mustafa A. Maher
  • Publication number: 20150079083
    Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
    Type: Application
    Filed: July 7, 2014
    Publication date: March 19, 2015
    Inventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
  • Publication number: 20150080288
    Abstract: Nitration shielding peptides that reduce or prevent nitration of a protein of interest are disclosed. The peptide can serve as molecular sink for nitrating agents, block access of the nitrating agents to the target tyrosine on the protein of interest, serve as substrate for the nitrating agent (i.e., provide an alternative nitratable tyrosine residue), provide a nitrating agent neutralizing moiety such as antioxidant, or a combination thereof. The nitration shielding peptide can be a fusion protein that includes one or more additional domains such a protein transduction domain, a targeting signal, a purification tag, or any combination thereof. Exemplary nitration shielding peptides for reducing nitration of RhoA and PKG-1?, and methods of use thereof for treating pathologies, disease, and disorders associated with nitration of RhoA and PKG-1?, respectively are also provided.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 19, 2015
    Inventors: Stephen M. Black, Ruslan Robertovich Rafitov
  • Patent number: 8980271
    Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: March 17, 2015
    Assignee: Ipierian, Inc.
    Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Cao Dang
  • Patent number: 8969077
    Abstract: The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding Caveolin-1.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: March 3, 2015
    Assignee: The Regents of the University of California
    Inventors: Brian P. Head, Piyush M. Patel, Hemal Patel, David M. Roth
  • Patent number: 8968734
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: March 3, 2015
    Assignee: BioArctic Neuroscience AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Publication number: 20150051138
    Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Alex Strongin, Maurizio Pellecchia, Elisa Barile
  • Publication number: 20150051151
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
  • Publication number: 20150050215
    Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
    Type: Application
    Filed: September 14, 2012
    Publication date: February 19, 2015
    Applicant: Axon Neuroscience SE
    Inventors: Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka
  • Patent number: 8957030
    Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 17, 2015
    Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de Montreal
    Inventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
  • Publication number: 20150038402
    Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Inventors: DAVID PAUL FAIRLIE, LIGONG LIU, MEI KWAN YAU, JACKY YUNG SUEN, ROBERT REID
  • Publication number: 20150038426
    Abstract: Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, disclosed herein are methods of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.
    Type: Application
    Filed: October 20, 2014
    Publication date: February 5, 2015
    Inventors: Michael J. Pugia, Rui Ma
  • Patent number: 8945576
    Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: February 3, 2015
    Assignees: Kyoto University, National Institute of Radiological Sciences
    Inventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
  • Patent number: 8946165
    Abstract: The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 3, 2015
    Assignee: The Regents of the University of California
    Inventors: Eliezer Masliah, Brian Spencer, Edward Rockenstein, Robert Marr
  • Patent number: 8940306
    Abstract: An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid ? peptide that induces an enhanced immune response. An amyloid ? peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid ? peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid ? peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: January 27, 2015
    Assignee: The Chemo-Sero-Therapeutic Research Institute
    Inventors: Junichi Matsuda, Kazuyoshi Kaminaka, Chikateru Nozaki
  • Publication number: 20150025014
    Abstract: In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibrillization of peptides implicated in the amyloidoses, especially the amyloid-b eta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof.
    Type: Application
    Filed: April 30, 2014
    Publication date: January 22, 2015
    Inventor: William E. van Nostrand
  • Patent number: 8937218
    Abstract: A transformed soybean plant having a gene encoding a modified seed storage protein introduced therein, obtained by inserting a gene encoding an Alzheimer's disease vaccine to a variable region(s) of a gene encoding a wild-type seed storage protein, is produced, and said vaccine is produced and accumulated in the seeds thereof.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: January 20, 2015
    Assignee: Hokko Chemical Industry Co., Ltd.
    Inventors: Teruhiko Terakawa, Hisakazu Hasegawa, Masao Ishimoto, Mikio Shoji, Takeshi Kawarabayashi, Yasuko Utsumi
  • Patent number: 8937039
    Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: January 20, 2015
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
  • Publication number: 20150018269
    Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.
    Type: Application
    Filed: August 24, 2012
    Publication date: January 15, 2015
    Applicants: UNIVERSITÄT ZU KÖLN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Ronald Kühne, Hartmut Oschkinat, Robert Opitz, Matthias Müller, Hans-Günther Schmalz, Cedric Reuter, Peter Huy
  • Publication number: 20150018278
    Abstract: The object of the invention is based on inhibiting specific phosphorylation on Thr248 and/or Thr250 residues of human transcription factor E2F4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of E2F4 without Thr residues phosphorylated by p38MAPK) or methods developed in the future that may be applied to Thr-248 and/or Thr-250 residues of human transcription factor E2F4.
    Type: Application
    Filed: November 15, 2012
    Publication date: January 15, 2015
    Inventor: Jose Maria Frade Lopez